What to expect from the newest drugs.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000932:Antiemetics / Q000627:therapeutic use; D013759:Dronabinol / Q000031:analogs & derivatives / Q000627:therapeutic use; D004358:Drug Therapy; D005047:Etoposide / Q000627:therapeutic use; D005480:Flurbiprofen / Q000627:therapeutic use; D005640:Follicle Stimulating Hormone / Q000627:therapeutic use; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use; D009241:Ipratropium / Q000627:therapeutic use; D008148:Lovastatin / Q000627:therapeutic use; D011224:Prazosin / Q000031:analogs & derivatives / Q000627:therapeutic use; D011412:Propanolamines / Q000627:therapeutic use; D013300:Streptokinase / Q000627:therapeutic use; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014148:Tranexamic Acid / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000900:Anti-Bacterial Agents; D000932:Antiemetics; D007376:Interleukin-2; D011412:Propanolamines; C011941:nabilone; D005480:Flurbiprofen; D005047:Etoposide; D014148:Tranexamic Acid; D013759:Dronabinol; C041226:Terazosin; D005640:Follicle Stimulating Hormone; D008148:Lovastatin; D013300:Streptokinase; D010959:Tissue Plasminogen Activator; D009241:Ipratropium; C036604:esmolol; D011224:Prazosin